Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
The current Alnylam Pharmaceuticals(ALNY) stock price is $400.23, with a market capitalization of 52.93B. The stock trades at a price-to-earnings (P/E) ratio of 1664.85.
During the trading session on 2025-12-20, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $408.14 and a low of $396.06. At a current price of $400.23, the stock is +1.1% higher than the low and still -1.9% under the high.
Trading volume for Alnylam Pharmaceuticals(ALNY) stock has reached 12.56M, versus its average volume of 2.63M.
Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.
Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.
ALNY News
Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...
Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available this week, for the February 2026 expiration. At Stock Options Channel ,...
(RTTNews) - Alnylam Pharmaceuticals (ALNY) on Wednesday said it plans to expand its manufacturing facility in Norton, Massachusetts, with an investment of about...
Analyst ratings
68%
of 31 ratingsMore ALNY News
Alnylam (ALNY) announced the planned expansion of its manufacturing facility in Norton, Massachusetts. The company is preparing to invest $250M to advance what...
Alnylam Pharmaceuticals recently reshaped its governance and capital structure, with two long-serving directors stepping down, a new independent director appoin...
Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, t...
The Nasdaq-100 Index has announced its annual reconstitution, adding six new companies and removing six, effective Dec. 22. Six Stocks Added, Six Dropped From...
The Nasdaq (NDAQ) reshuffles its Nasdaq-100 index (NDX) annually in December, and the company announced six new additions to its coveted index this year. The ND...
Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst on December 12. Analyst Michael Ulz from Morgan Stanley maintained a Hold...
Alnylam Pharmaceuticals (ALNY) just hit a fresh milestone, landing a spot in the Nasdaq 100 while simultaneously moving to repurchase a slice of its 2027 conver...